Literature DB >> 6403472

The in vitro activity of ceftazidime against a multi-resistant serotype 12 Pseudomonas aeruginosa.

G Ninane, P B Harper.   

Abstract

Highly resistant isolates of Pseudomonas aeruginosa serotype 12 accounted for 42.2% of the pseudomonads isolated from patients in a 600-bed hospital over a period of 18 months. In vitro studies showed that this organism was resistant to tobramycin, gentamicin, apalcillin, piperacillin, azlocillin, ticarcillin, cefotaxime and cefsulodin. All serotype 12 isolates were completely sensitive to ceftazidime. Its geometric mean MIC was 3.4 mg/l. This new cephalosporin seems promising for the treatment of patients infected with pseudomonas, especially when a resistant strain such as serotype 12 is involved.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6403472     DOI： 10.1007/BF01641099

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  10 in total

1.  Comparative in vitro activity of tobramycin, gentamicin, kanamycin, colistin, carbenicillin, and ticarcillin and clinical isolates of Pseudomonas aeruginosa: epidemiological and therapeutic implications.

Authors:  H L Dulong de Rosnay; P A Grimont; B Dessaut; M T Lesgouarres
Journal:  J Infect Dis       Date:  1976-08       Impact factor: 5.226

2.  Serological typing of Pseudomonas aeruginosa--comparison of various antigenic schema.

Authors:  J Y Homma; Y Hirao; K Saku; Y Terada; J I Sugiyama
Journal:  Jpn J Exp Med       Date:  1977-06

3.  Serological survey of Pseudomonas aeruginosa strains isolated from patients in Canadian hospitals.

Authors:  H Sato; B B Diena
Journal:  Can J Microbiol       Date:  1974-04       Impact factor: 2.419

4.  Multiple of isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis.

Authors:  M J Thomassen; C A Demko; B Boxerbaum; R C Stern; P J Kuchenbrod
Journal:  J Infect Dis       Date:  1979-12       Impact factor: 5.226

5.  Serological typing of Pseudomonas aeruginosa: use of commercial antisera and live antigens.

Authors:  C D Brokopp; R Gomez-Lus; J J Farmer
Journal:  J Clin Microbiol       Date:  1977-06       Impact factor: 5.948

6.  Susceptibility of recent isolates of Pseudomonas aeruginosa to gentamicin, polymyxin, and five penicillins, with observations on the pyocin and immunotypes of the strains.

Authors:  J L Adler; M Finland
Journal:  Appl Microbiol       Date:  1971-11

7.  GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.

Authors:  C H O'Callaghan; P Acred; P B Harper; D M Ryan; S M Kirby; S M Harding
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

8.  GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae.

Authors:  L Verbist; J Verhaegen
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

9.  Characterization of Pseudomonas species isolated from clinical specimens.

Authors:  G L Gilardi
Journal:  Appl Microbiol       Date:  1971-03

10.  Tobramycin and gentamicin concentrations in the serum of normal and anephric patients.

Authors:  W R Lockwood; J D Bower
Journal:  Antimicrob Agents Chemother       Date:  1973-01       Impact factor: 5.191
  10 in total
  2 in total

1.  Virulence determinants in Pseudomonas aeruginosa strains from urinary tract infections.

Authors:  P Visca; F Chiarini; A Mansi; C Vetriani; L Serino; N Orsi
Journal:  Epidemiol Infect       Date:  1992-04       Impact factor: 2.451

2.  Marked increase of Pseudomonas aeruginosa serotype 012 in Belgium since 1982.

Authors:  D Allemeersch; J Beumer; M Devleeschouwer; S De Maeyer; J Dony; C Godard; P Osterrieth; A Pithsy; P Van der Auwera; H Van Poppel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-04       Impact factor: 3.267
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.